BioNxt Solutions | Revolutionary Drug Delivery for MS and Beyond

StockBox

10.8K subscribers

ShareSubscribe

BioNxt Solutions | Revolutionary Drug Delivery for MS and Beyond StockBox spoke with Hugh Rogers, CEO of BioNxt Solutions (CSE: BNXT) (FSE:BXT), to discuss their innovative sublingual drug delivery platform set to transform treatment for neurological autoimmune diseases like MS and myasthenia gravis. By repurposing already-approved blockbuster drugs into oral dissolvable films, BioNxt offers a low-risk, fast-track route to market, with key human trial results expected within 3–6 months. Beyond these initial targets, the company is building a scalable pipeline including longevity treatments, supported by global patent filings and potential licensing deals. 🔹 Key Highlights: ✅ Bionxt’s patented drug delivery system for blockbuster MS drug Cladribine ✅ Upcoming bioequivalence human pilot trials (results expected in 3–6 months) ✅ Fast-track development with lower risk and cost compared to traditional pharma. ✅ Plans for global patent filings in the US, Japan, Canada, and Australia ✅ Exciting future pipeline including a move into the longevity and wellness sector 🔗 Latest Research Talks Video: https://www.youtube.com/watch?v=fAojFIt19eU 📩 Sign up for our newsletter: https://mailchi.mp/stockboxmedia.com/ 🐦 Follow us on X: https://x.com/StockBoxMedia #Bionxt #BiotechStocks #PharmaceuticalInnovation #MultipleSclerosis #DrugDelivery #InvestmentOpportunities #Sublingual #LongevityResearch #ClinicalTrials #StockboxMedia